China’s quantitative fund sector has undergone a structural transformation over the past twelve months. According to Bloomberg data reported by Business Mirror, assets under management in Chinese quant funds more than doubled in under a year to 2.6 trillion yuan ($381 billion). The driver is not just capital flows, but rather performance.
In late June 2026, Alibaba’s Qwen team released Qwen-AgentWorld-35B-A3B under an Apache 2.0 license, a model that does something conceptually unusual: it generates entirely fictional training environments to teach AI agents how to act in the real world. The approach, analyzed in depth by Towards AI, produced a striking result.
China’s AI companion market is undergoing a forced restructuring. On July 3, ByteDance’s Doubao and Alibaba’s Tongyi Qianwen simultaneously announced that they would discontinue consumer-facing user-customized AI agent features on July 15.
Huawei and state-backed carrier China Mobile have announced a successful validation of what they describe as China’s first carrier-grade AI inference system built on domestic chips.
What UBTech announced in Shenzhen UBTech unveiled the UWORLD U1 line at a June 30 global launch in Shenzhen, presenting what the company calls the world’s first full-size, mass-produced ultra‑bionic humanoid companion.
Ant Group’s lead in a 500 million yuan pre-Series A for Zeroth Robotics signals a new phase for China’s companion-robot market: rapidly rising revenues, meaningful order books and an expanding investor roster that includes strategic automotive and entertainment players.
While U.S. export controls have severely restricted Nvidia’s ability to sell its most advanced artificial intelligence training chips to Chinese customers, the Silicon Valley giant is quietly but aggressively expanding its footprint in another critical sector of the Chinese tech ecosystem: robotics.
The consumer market for humanoid robots is materializing faster than many industry analysts predicted. UBTech, the Shenzhen-based robotics pioneer, has secured approximately 5,000 pre-orders for its newly announced Walker U1 consumer humanoid robot in just four weeks.
The transition of humanoid robots from highly choreographed laboratory demonstrations to functional industrial deployment has taken a significant step forward. AgiBot, a prominent Shanghai-based robotics startup also known as Zhiyuan Robotics, has successfully completed a grueling six-day factory trial at Longcheer Technology’s manufacturing facility in Nanchang.
The convergence of artificial intelligence and biotechnology in China has reached a new milestone with the groundbreaking of the country’s first production line for AI-assisted personalized tumor vaccines in Beijing.
Chinese technology giant Tencent is bringing advanced artificial intelligence directly to the enterprise desktop with the launch of Dayuan, a new AI assistant integrated into WeCom, its widely used workplace collaboration platform.
The application of artificial intelligence to pharmaceutical research continues to generate massive commercial partnerships, underscoring the industry’s belief in AI’s potential to revolutionize drug discovery. In the latest major development, Hong Kong-headquartered Insilico Medicine has entered into a strategic research and development collaboration with South Korea’s SK Biopharmaceuticals.
The intersection of artificial intelligence and national security has taken a dramatic turn as Qihoo 360, one of China’s largest cybersecurity firms, unveiled a suite of AI-powered security tools explicitly designed to rival the capabilities of Anthropic’s restricted Claude Mythos model.
The Mobile World Congress (MWC) Shanghai 2026 provided the stage for a unique and highly revealing spectacle: the first-ever fully autonomous humanoid robot penalty shootout. While the event drew massive crowds and generated viral social media clips of robots clumsily kicking footballs, the underlying purpose was far more serious.
China’s UBTECH Robotics is executing one of the most aggressive multi-market expansions in the humanoid robotics industry, simultaneously targeting government infrastructure, commercial service environments, and the consumer market.
JD.com founder and chairman Richard Liu has issued a stark warning about the future of the company’s workforce, stating publicly that robots will “sooner or later” replace the e-commerce giant’s 700,000 delivery workers.
Morgan Stanley has sharply raised its outlook for China’s humanoid robotics market for the second time this year, doubling its shipment forecast to 50,000 units for 2026, according to The Next Web and the South China Morning Post.
Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to leverage the Shanghai-based biotech’s drug discovery and early development capabilities, built on a multi-dimensional platform integrating computational chemistry, cancer genomics, and translational science, across multiple undisclosed targets, Fierce Biotech reported.
China’s Ministry of Industry and Information Technology (MIIT) and the State-owned Assets Supervision and Administration Commission (SASAC) have jointly launched a national program to accelerate the commercial deployment of humanoid robots, setting a target of integrating more than 10,000 units into the workforce across 100 designated “premium application scenarios” by the end of 2026.
Chinese electric vehicle giant BYD has published a new patent for an artificial intelligence-powered underbody vision system designed to detect living organisms beneath parked vehicles before the car begins to move.
